Illumina, Inc. (NASDAQ:ILMN) Upgraded to Sell by BidaskClub

Illumina, Inc. (NASDAQ:ILMN) was upgraded by BidaskClub from a “strong sell” rating to a “sell” rating in a research note issued to investors on Tuesday.

A number of other equities analysts also recently issued reports on ILMN. Zacks Investment Research raised Illumina from a “hold” rating to a “buy” rating and set a $191.00 price target for the company in a report on Tuesday, April 4th. Vetr raised Illumina from a “buy” rating to a “strong-buy” rating and set a $190.90 price target for the company in a report on Tuesday, April 4th. Leerink Swann reaffirmed a “buy” rating on shares of Illumina in a report on Wednesday, April 5th. TheStreet raised Illumina from a “c+” rating to a “b” rating in a report on Thursday, April 6th. Finally, Bank of America Corporation upped their price target on Illumina from $175.00 to $195.00 and gave the company a “buy” rating in a report on Tuesday, April 11th. Three analysts have rated the stock with a sell rating, ten have given a hold rating and ten have given a buy rating to the stock. Illumina currently has an average rating of “Hold” and an average price target of $174.38.

Shares of Illumina (ILMN) traded up 0.23% on Tuesday, reaching $198.31. The company’s stock had a trading volume of 1,603,560 shares. The company has a market cap of $28.95 billion, a PE ratio of 40.14 and a beta of 0.83. Illumina has a 52-week low of $119.37 and a 52-week high of $198.57. The firm has a 50 day moving average of $174.66 and a 200 day moving average of $171.89.

Illumina (NASDAQ:ILMN) last announced its quarterly earnings results on Tuesday, August 1st. The life sciences company reported $0.82 earnings per share (EPS) for the quarter, beating the Zacks’ consensus estimate of $0.68 by $0.14. The firm had revenue of $662 million during the quarter, compared to the consensus estimate of $642.38 million. Illumina had a return on equity of 20.39% and a net margin of 30.27%. The firm’s quarterly revenue was up 10.3% compared to the same quarter last year. During the same period in the prior year, the company posted $0.86 earnings per share. Analysts predict that Illumina will post $3.63 earnings per share for the current year.

TRADEMARK VIOLATION NOTICE: This article was originally published by [[site]] and is owned by of [[site]]. If you are viewing this article on another domain, it was copied illegally and republished in violation of international trademark & copyright legislation. The original version of this article can be accessed at [[permalink]].

In other news, Director Jay T. Flatley sold 20,000 shares of the company’s stock in a transaction that occurred on Tuesday, May 9th. The stock was sold at an average price of $184.14, for a total transaction of $3,682,800.00. Following the completion of the sale, the director now owns 539,176 shares in the company, valued at $99,283,868.64. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available through the SEC website. Also, SVP Charles Dadswell sold 145 shares of the company’s stock in a transaction that occurred on Monday, June 5th. The stock was sold at an average price of $184.75, for a total value of $26,788.75. Following the sale, the senior vice president now owns 10,791 shares of the company’s stock, valued at approximately $1,993,637.25. The disclosure for this sale can be found here. Insiders sold 123,639 shares of company stock valued at $21,980,677 over the last three months. Corporate insiders own 1.60% of the company’s stock.

Several large investors have recently added to or reduced their stakes in the company. Nisa Investment Advisors LLC boosted its stake in Illumina by 41.0% in the first quarter. Nisa Investment Advisors LLC now owns 6,190 shares of the life sciences company’s stock valued at $1,056,000 after buying an additional 1,800 shares during the period. State of Tennessee Treasury Department boosted its stake in Illumina by 7.8% in the first quarter. State of Tennessee Treasury Department now owns 97,850 shares of the life sciences company’s stock valued at $16,697,000 after buying an additional 7,040 shares during the period. Aberdeen Asset Management PLC UK boosted its stake in Illumina by 8.4% in the first quarter. Aberdeen Asset Management PLC UK now owns 27,981 shares of the life sciences company’s stock valued at $4,775,000 after buying an additional 2,158 shares during the period. Bank of Nova Scotia boosted its stake in Illumina by 265.4% in the first quarter. Bank of Nova Scotia now owns 86,202 shares of the life sciences company’s stock valued at $14,710,000 after buying an additional 62,612 shares during the period. Finally, Eastern Bank bought a new stake in Illumina during the first quarter valued at approximately $256,000. Institutional investors and hedge funds own 93.68% of the company’s stock.

About Illumina

Illumina, Inc (Illumina) is a provider of sequencing- and array-based solutions for genetic analysis. The Company operates through two segments: Core Illumina and the consolidated variable interest entities (VIEs), which include the activities of GRAIL, Inc (GRAIL) and Helix Holdings I, LLC (Helix). Core Illumina consists of its core operations.